David Sweeny

Title: David Sweeny: Innovator in IRAK Inhibitor Compounds

Introduction

David Sweeny is a notable inventor based in South San Francisco, CA. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that inhibit interleukin receptor associated kinases (IRAK). His work is crucial in addressing diseases associated with IRAK.

Latest Patents

David Sweeny holds a patent for "Pyrimid-2-yl-pyrazole compounds as IRAK inhibitors." This patent discloses novel compounds and compositions that may be used to treat or prevent IRAK-associated diseases or conditions. The compounds are characterized by a specific structure according to Formula I. Additionally, the patent outlines methods for making and utilizing these compounds and compositions.

Career Highlights

David Sweeny is currently employed at Rigel Pharmaceuticals, Incorporated, where he continues to innovate in the pharmaceutical sector. His work focuses on developing therapies that target critical pathways in disease processes, showcasing his commitment to advancing medical science.

Collaborations

David collaborates with talented individuals in his field, including Jack Maung and Yan Chen. Their combined expertise contributes to the innovative environment at Rigel Pharmaceuticals.

Conclusion

David Sweeny is a prominent figure in the development of IRAK inhibitors, with a patent that holds promise for treating significant health conditions. His work at Rigel Pharmaceuticals exemplifies the impact of innovation in the pharmaceutical industry.